On December 10, Sanofi announced that its world's first and only innovative siRNA nonfactorial therapy for hemophilia, has been officially approved for marketing by the China National Drug Administration. It is suitable for routine preventive treatment of children and adults aged 12 and above with the following diseases to prevent bleeding or reduce the frequency of hemorrhagic attacks: severe type A hemophilia with or without coagulation factor VIII inhibitors or severe type B hemophilia with or without coagulation factor IX inhibitors.

On December 10, Sanofi announced that its world's first and only innovative siRNA nonfactorial therapy for hemophilia, has been officially approved for marketing by the China National Drug Administration. It is suitable for routine preventive treatment of children and adults aged 12 and above with the following diseases to prevent bleeding or reduce the frequency of hemorrhagic attacks: severe type A hemophilia with or without coagulation factor VIII inhibitors or severe type B hemophilia with or without coagulation factor IX inhibitors.